{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:48:10Z","timestamp":1784566090385,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40121-020-00351-0","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T19:02:36Z","timestamp":1602788556000},"page":"1017-1028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-936X","authenticated-orcid":false,"given":"Nicholas","family":"Van Hise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell M.","family":"Petrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Skorodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Fliegelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Didwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Chundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Roig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorv","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"351_CR1","unstructured":"O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016."},{"key":"351_CR2","unstructured":"WHO publishes list of bacteria for which new antibiotics are urgently needed [press release]. Geneva, 27 February 2017."},{"key":"351_CR3","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMoa1408913","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, Winston LG, McDonald LC. Emerging infections program C. difficile surveillance team. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:2369\u201370.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"351_CR4","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1093\/cid\/cis335","volume":"55","author":"ER Dubberke","year":"2012","unstructured":"Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88\u2013S89.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"351_CR5","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH, Starosta AL, Fyfe C, Brien W, Rothstein DM, Mikolajka A, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56(5):2559.","journal-title":"Antimicrob Agents Chemother"},{"key":"351_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567\u201388. https:\/\/doi.org\/10.1007\/s40265-016-0545-8.","journal-title":"Drugs"},{"key":"351_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","volume":"79","author":"LJ Scott","year":"2019","unstructured":"Scott LJ. Eravacycline: a review in complicated intra-abdominal infections. Drugs. 2019;79:315\u201324. https:\/\/doi.org\/10.1007\/s40265-019-01067-3.","journal-title":"Drugs"},{"key":"351_CR8","unstructured":"Tetraphase pharmaceuticals announces FDA approval of XERAVA\u2122 (ERAVACYCLINE) for complicated intra-abdominal infections (CIAI) [press release]. 2018."},{"key":"351_CR9","unstructured":"Joseph S, Mathias T. FDA approves Tetraphase Pharma's antibiotic. Reuters. 2018 August 27 2018; Sect. Health News"},{"key":"351_CR10","unstructured":"Cox E. NDA APPROVAL: XERAVA (eravacycline) for injection. In: FDA. Silver Spring, MD: Department of Health and Human Services; 2018."},{"key":"351_CR11","unstructured":"European Medicines Agency. Xerava (eravacycline) Amsterdam, The Netherlands: European Medicines Agency; 2018 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xerava."},{"key":"351_CR12","doi-asserted-by":"crossref","unstructured":"Basseres E, Miranda J, Gonzales-Luna A, Carlson T, Rashid T, Jahangir Alam M, et al. In vitro acivity of eravacycline, a new tetracycline analog, and comparators against the six most commonly isolated Ribotypes of Clostridioides difficile. Poster #2398. ID Week; 2019 October 2; Washington D.C, USA.","DOI":"10.1093\/ofid\/ofz360.756"},{"key":"351_CR13","unstructured":"Olesky M, Morrissey I, Hawser S, Magnet S, Guemmaz A, Monti F, et al. P0099 In vitro activity of eravacycline and comparators against resistant Gram negative isolates collected in 2016 from patients in Europe. 28th ECCMID European Congress of Clinical Microbiology and Infectious Diseases; 21 April 2018; Madrid, Spain 2018."},{"issue":"11","key":"351_CR14","doi-asserted-by":"publisher","first-page":"e01174","DOI":"10.1128\/AAC.01174-18","volume":"62","author":"JV Newman","year":"2018","unstructured":"Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother. 2018;62(11):e01174\u2013e1218.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"351_CR15","doi-asserted-by":"crossref","first-page":"e01810","DOI":"10.1128\/AAC.01810-18","volume":"63","author":"JV Newman","year":"2019","unstructured":"Newman JV, Zhou J, Izmailyan S, Tsai L. Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother. 2019;63(3):e01810\u2013e1818.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"351_CR16","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/ofid\/ofx163.1359","volume":"4","author":"P Horn","year":"2017","unstructured":"Horn P, Redican S, Olesky M. Pharmacokinetics (PK) of eravacycline in subjects with renal or hepatic impairment compared with healthy subjects. Open Forum Infect Dis. 2017;4(1):S521\u2013S522522.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"351_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152(3):224\u201332.","journal-title":"JAMA Surg"},{"issue":"6","key":"351_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","volume":"69","author":"JS Solomkin","year":"2019","unstructured":"Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019;69(6):921\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"351_CR19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3390\/jcm8060866","volume":"8","author":"S-H Lan","year":"2019","unstructured":"Lan S-H, Chang S-P, Lai C-C, Lu L-C, Chao C-M. The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: a systemic review and meta-analysis of randomized controlled trials. J Clin Med. 2019;8(6):866.","journal-title":"J Clin Med"},{"key":"351_CR20","unstructured":"Lunsted S, Molina K, Barber GR, Huang M, Miller M. Real-World use of Eravcycline: A case series. Poster 011. ASHP Midyear Clinical Meeting & Exhibition; December 8\u201312, 2019; Las Vegas, NV, USA 2019."},{"key":"351_CR21","unstructured":"Hwang SL. Real-world utilization of eravacycline in the outpatient setting Abstract No. 22. MAD ID; May 27\u201330; Orlando, FL, USA 2020."},{"key":"351_CR22","unstructured":"Parkingson J. Eravacycline Realizes Successful Clinical Endpoint in OPAT Facilities Cranbury, NJ, USA: Contagion Infectious Diseases Today; 2020 [Available from: https:\/\/www.contagionlive.com\/news\/eravacycline-realizes-successful-clinical-endpoint-opat-facilities."},{"issue":"5","key":"351_CR23","doi-asserted-by":"publisher","first-page":"ofss071","DOI":"10.1093\/ofid\/ofaa071","volume":"7","author":"S Alosaimy","year":"2020","unstructured":"Alosaimy S, Molina KC, Claeys KC, Andrade J, Truong J, King MA, et al. Early experience with eravacycline for complicated infections. Open Forum Infect Dis. 2020;7(5):ofss071.","journal-title":"Open Forum Infect Dis."},{"issue":"1","key":"351_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s40801-020-00189-5","volume":"7","author":"M Redell","year":"2020","unstructured":"Redell M. Real-world evidence studies of oritavancin use in gram-positive infections augment randomized controlled trials to address clinical and economic outcomes. Drugs Real World Outcomes. 2020;7(1):2\u20135.","journal-title":"Drugs Real World Outcomes"},{"issue":"2","key":"351_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40121-014-0050-x","volume":"3","author":"NS Britt","year":"2014","unstructured":"Britt NS, Steed ME, Potter EM, Clough LA. Tigecycline for the treatment of severe and severe complicated Clostridium difficile infection. Infect Dis Ther. 2014;3(2):321\u201331.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"351_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1248\/bpb.35.967","volume":"35","author":"K Kadoyama","year":"2012","unstructured":"Kadoyama K, Sakaeda T, Tamon A, Okuno Y. Adverse event profile of tigecycline: data mining of the public version of the US Food and Drug Administration Adverse Event Reporting System. Biol Pharma Bull. 2012;35(6):967\u201370.","journal-title":"Biol Pharma Bull"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-020-00351-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:18:27Z","timestamp":1634257107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-020-00351-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00351-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}